Femhrt
Product Images NDC 54868-4679

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Femhrt (NDC 54868-4679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula Of Ethinyl Estradiol (2436701d 972d 46fc 8c20 496fde55bd98 01)

Chemical structure diagram of the active ingredient in Femhrt showing a steroidal core with hydroxyl groups and an alkyne side chain, consistent with an estrogen hormone structure.*

FDA Label Image

Structural Formula Of Norethindrone Acetate (2436701d 972d 46fc 8c20 496fde55bd98 02)

Chemical structure of the active ingredient shown on the femhrt product image, depicting a steroidal compound with a complex four-ring core, multiple hydroxyl and ketone groups, and an ester side chain characteristic of hormone therapy medications.*

FDA Label Image

Figure 1. (2436701d 972d 46fc 8c20 496fde55bd98 03)

Two pharmacokinetic line graphs showing mean plasma concentrations of two substances over 24 hours. The top graph displays mean plasma norethindrone concentration (ng/mL) versus time (hours), and the bottom graph shows mean plasma ethinyl estradiol concentration (pg/mL) versus time (hours). Both graphs plot concentration changes during a 24-hour period after dosing.*

FDA Label Image

Warner Chilcott Logo (2436701d 972d 46fc 8c20 496fde55bd98 04)

Femhrt tablet carton by Physicians Total Care, Inc., labeled with product NDC 54868-4679. The front panel shows the proprietary name femhrt and the labeler. The packaging is primarily gray with a blue Warner Chilcott logo on the left side.*

FDA Label Image

Figure 3. Mean Percent Change (+se) From Baseline In Volumetric Bone Mineral Density At Lumbar Spine Measured By Quantitative Computed Tomography After 12 And 24 Months Of Treatment (intent-to-treat Population) (2436701d 972d 46fc 8c20 496fde55bd98 11)

A bar chart showing mean percent change from baseline in volumetric bone mineral density at the lumbar spine after 12 and 24 months of treatment, comparing placebo, Femhrt 0.5/2.5, and Femhrt 1/5 groups. The chart indicates significant increases in bone mineral density for both Femhrt doses compared to placebo at both time points.*

FDA Label Image

Figure 2. Patients With Cumulative Amenorrhea Over Time: Intent-to-treat Population. Last Observation Carried Forward (2436701d 972d 46fc 8c20 496fde55bd98 12)

A line graph titled 'Patients With Cumulative Amenorrhea Over Time' showing data for placebo, femhrt 0.5/2.5, and femhrt 1/5 groups over 12 months of treatment. The y-axis represents percentage of patients, and the x-axis shows months of treatment at intervals of 1, 3, 6, 9, and 12. Three lines indicate cumulative amenorrhea percentages for each group, with placebo consistently highest and femhrt 1/5 lowest.*

FDA Label Image

Femhrt 5 Pouches Trade Carton- 1 mg / 5mcg (Package Label)

Label for femhrt 1 mg/5 mcg tablets distributed by Physicians Total Care, Inc. The label includes the product NDC 54868-4679-0, an expiration date formatted as 01/60, and identifies Warner Chilcott Company, Inc. as the manufacturer. A barcode is present at the bottom of the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.